Alpha 2.0
Login Register
» Authors » Suthinee Ithimakin

Suthinee Ithimakin

Explore the profile of Suthinee Ithimakin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 24
Citations 556
Followers 0
Related Specialties
Oncology
General Medicine
Gastroenterology
Top 10 Co-Authors
Charuwan Akewanlop
Vichien Srimuninnimit
Nopadol Soparattanapaisarn
Janjira Petsuksiri
Atthaphorn Trakarnsanga
Concord Wongkraisri
Akarin Nimmannit
Leena Chularojanamontri
Lucksamon Thamlikitkul
Shawn G Clouthier
Published In
BMC Cancer
J Med Assoc Thai
Support Care Cancer
Asian Pac J Cancer Prev
JCO Glob Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome
Wongkraisri C, Chusuwanrak K, Laocharoenkeat A, Chularojanamontri L, Nimmannit A, Ithimakin S
BMC Cancer . 2025 Feb; 25(1):275. PMID: 39962445
Background: Hand-foot syndrome (HFS) is a common adverse event of capecitabine causing treatment modifications. Topical urea cream can reduce sorafenib-induced hand-foot skin reaction. However, its benefit in preventing capecitabine-associated HFS...
2.
Efficacy and Safety of Short Intravenous Hydration for Preventing Nephrotoxicity From High-Dose Cisplatin: A Randomized, Open-Label, Phase II Trial
Jantarat A, Thamlikitkul L, Thephamongkhol K, Setakornnukul J, Phisalprapa P, Kositamongkol C, et al.
JCO Glob Oncol . 2025 Jan; 11():e2400515. PMID: 39819128
Purpose: The use of short hydration (SH) to prevent cisplatin-induced nephrotoxicity lacks substantive prospective evaluation. The aim of this study was to evaluate the safety and efficacy of SH, including...
3.
Efficacy and safety of nail gutter therapy and topical timolol for treating epidermal growth factor receptor inhibitor-induced nail changes: A randomized, single-blind, intraindividual study
Yenyuwadee I, Yenyuwadee S, Rujitharanawong C, Leeyaphan C, Eimpunth S, Ithimakin S, et al.
J Am Acad Dermatol . 2024 Nov; 92(3):617-619. PMID: 39547324
No abstract available.
4.
Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand
Dajsakdipon T, Susiriwatananont T, Wongkraisri C, Ithimakin S, Parinyanitikul N, Supavavej A, et al.
BMC Cancer . 2024 Aug; 24(1):1018. PMID: 39152401
Background: The current standard first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR + /HER2 -) advanced breast cancer (ABC) is a combination of aromatase inhibitor (AI)...
5.
Follow-Up Strategies and Detection of Recurrent Breast Cancer in the Modern Era
Ithimakin S, Luengwatthanakit N, Wongkraisri C
Asian Pac J Cancer Prev . 2023 Apr; 24(4):1359-1366. PMID: 37116159
Background: Regular history assessments and physical examination with annual breast imaging have been recommended as the standard surveillance protocol for breast cancer patients who underwent curative-intent therapy. Based on randomized...
6.
Outcomes of Patients With Breast Cancer Treated With or Without Internal Mammary Irradiation: A Single-Center, Retrospective Propensity Score-Matched Study
Jitwatcharakomol T, Setakoranukul J, Ithimakin S, Krittayaphong R, Thephamongkhol K
Adv Radiat Oncol . 2022 Dec; 8(1):101072. PMID: 36483062
Purpose: Internal mammary lymph node radiation therapy (IMN-RT) has unclear benefits. Historical data were based on only conventional (2-dimensional) radiation techniques. In this 3-dimensional radiation therapy era, we compared the...
7.
Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories
Ithimakin S, Parinyanitikul N, Kim S, Yap Y, Tsang J, Soong I, et al.
J Breast Cancer . 2022 Jun; 25(3):207-217. PMID: 35657002
Purpose: Breast cancer (BC) treatment has shifted from chemotherapy to targeted therapy. Several targeted agents have demonstrated an improvement in survival. Given that national healthcare resources were correlated with the...
8.
Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis
Ngamphaiboon N, Ithimakin S, Siripoon T, Sintawichai N, Sriuranpong V
BMC Cancer . 2021 Nov; 21(1):1275. PMID: 34823493
Background: Most immune-related adverse event (irAE) patterns and treatment guidelines are based on western clinical data. We evaluated the incidence and patterns of irAEs in patients treated with immune-checkpoint inhibitors...
9.
Predictive significance of cancer related-inflammatory markers in locally advanced rectal cancer
Timudom K, Akaraviputh T, Chinswangwatanakul V, Pongpaibul A, Korpraphong P, Petsuksiri J, et al.
World J Gastrointest Surg . 2020 Oct; 12(9):390-396. PMID: 33024513
Background: Locally advanced rectal cancer is treated using neoadjuvant chemoradiation (nCRT), followed by total mesorectal excision (TME). Tumor regression and pathological post-treatment stage are prognostic for oncological outcomes. There is...
10.
Association between dietary patterns and disease recurrence in Thai colorectal cancer patients
Kunnavuttivanich V, Pramyothin P, Ithimakin S
Medicine (Baltimore) . 2020 Mar; 99(11):e19522. PMID: 32176103
Beside established anti-cancer treatment, dietary modification is one of the most promising approaches for reducing the probability of colorectal cancer (CRC) recurrence. Many Western studies showed a relationship between shortened...